Stock Track | Guardant Health Soars 7.65% in After-Hours Trading on Q2 Revenue Beat and Raised 2026 Guidance

Stock Track07-31

Guardant Health Inc. shares surged 7.65% in after-hours trading on Thursday following the release of its second-quarter financial results, which showcased a significant revenue beat and an upward revision to its full-year revenue outlook.

The precision oncology company reported Q2 revenue of $335 million, easily surpassing the consensus estimate of $314.2 million and representing a 44% increase from the prior year. While adjusted loss per share of $0.42 slightly missed the analyst expectation of $0.41, investors focused on the robust top-line growth and the raised guidance. Guardant Health now expects full-year 2026 revenue between $1.34 billion and $1.36 billion, up from its previous forecast of $1.30 billion to $1.32 billion and above the FactSet consensus of $1.31 billion. The company also provided a 2026 screening revenue forecast of $218-$230 million, driven by Shield test volume of 270,000-285,000 tests.

The strong quarterly performance was driven by a 38% increase in oncology revenue, fueled by a 63% surge in oncology test volume, and a more than 250% jump in screening revenue, with Shield test volume rising to 66,000 from 16,000 in the year-ago period. Recent FDA approvals and expanded insurance coverage for the Shield blood test were cited as key growth catalysts by co-CEOs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183686285?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 04:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183686285","market":"sg","top_or_hot":-1,"title":"Stock Track | Guardant Health Soars 7.65% in After-Hours Trading on Q2 Revenue Beat and Raised 2026 Guidance","media":"Stock Track","content":"<p>Guardant Health Inc. shares surged 7.65% in after-hours trading on Thursday following the release of its second-quarter financial results, which showcased a significant revenue beat and an upward revision to its full-year revenue outlook.</p><p>The precision oncology company reported Q2 revenue of $335 million, easily surpassing the consensus estimate of $314.2 million and representing a 44% increase from the prior year. While adjusted loss per share of $0.42 slightly missed the analyst expectation of $0.41, investors focused on the robust top-line growth and the raised guidance. Guardant Health now expects full-year 2026 revenue between $1.34 billion and $1.36 billion, up from its previous forecast of $1.30 billion to $1.32 billion and above the FactSet consensus of $1.31 billion. The company also provided a 2026 screening revenue forecast of $218-$230 million, driven by Shield test volume of 270,000-285,000 tests.</p><p>The strong quarterly performance was driven by a 38% increase in oncology revenue, fueled by a 63% surge in oncology test volume, and a more than 250% jump in screening revenue, with Shield test volume rising to 66,000 from 16,000 in the year-ago period. Recent FDA approvals and expanded insurance coverage for the Shield blood test were cited as key growth catalysts by co-CEOs.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Guardant Health Soars 7.65% in After-Hours Trading on Q2 Revenue Beat and Raised 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Guardant Health Soars 7.65% in After-Hours Trading on Q2 Revenue Beat and Raised 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-31 04:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guardant Health Inc. shares surged 7.65% in after-hours trading on Thursday following the release of its second-quarter financial results, which showcased a significant revenue beat and an upward revision to its full-year revenue outlook.</p><p>The precision oncology company reported Q2 revenue of $335 million, easily surpassing the consensus estimate of $314.2 million and representing a 44% increase from the prior year. While adjusted loss per share of $0.42 slightly missed the analyst expectation of $0.41, investors focused on the robust top-line growth and the raised guidance. Guardant Health now expects full-year 2026 revenue between $1.34 billion and $1.36 billion, up from its previous forecast of $1.30 billion to $1.32 billion and above the FactSet consensus of $1.31 billion. The company also provided a 2026 screening revenue forecast of $218-$230 million, driven by Shield test volume of 270,000-285,000 tests.</p><p>The strong quarterly performance was driven by a 38% increase in oncology revenue, fueled by a 63% surge in oncology test volume, and a more than 250% jump in screening revenue, with Shield test volume rising to 66,000 from 16,000 in the year-ago period. Recent FDA approvals and expanded insurance coverage for the Shield blood test were cited as key growth catalysts by co-CEOs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1183686285","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183686285","pubTimestamp":1785444514,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Guardant Health Inc. shares surged 7.65% in after-hours trading on Thursday following the release of its second-quarter financial results, which showcased a significant revenue beat and an upward...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"股票跟踪 | Guardant Health 第二季度收入超出预期，盘后交易中股价飙升 7.65%，并上调了 2026 年指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"Guardant Health Inc. shares surged 7.65% in after-hours trading on Thursday following the release of its second-quarter financial results, which showcased a significant revenue beat and an upward revision to its full-year revenue outlook.The precision oncology company reported Q2 revenue of $335 million, easily surpassing the consensus estimate of $314.2 million and representing a 44% increase from the prior year. While adjusted loss per share of $0.42 slightly missed the analyst expectation of $0.41, investors focused on the robust top-line growth and the raised guidance. Guardant Health now expects full-year 2026 revenue between $1.34 billion and $1.36 billion, up from its previous forecast of $1.30 billion to $1.32 billion and above the FactSet consensus of $1.31 billion. The company also provided a 2026 screening revenue forecast of $218-$230 million, driven by Shield test volume of 270,000-285,000 tests.The strong quarterly performance was driven by a 38% increase in oncology revenue, fueled by a 63% surge in oncology test volume, and a more than 250% jump in screening revenue, with Shield test volume rising to 66,000 from 16,000 in the year-ago period. Recent FDA approvals and expanded insurance coverage for the Shield blood test were cited as key growth catalysts by co-CEOs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183686285","isCrawlerRequest":true}